CALLAN JMB INC. (CJMB)

Current Report Filed: 2026-04-10

Callan JMB Inc. received a deficiency letter from Nasdaq notifying the company that it is not in compliance with the minimum stockholders' equity requirement for continued listing.
The company has 45 days to submit a plan to regain compliance, and if accepted, Nasdaq may grant the company up to 180 days to evidence compliance.
The company's non-compliance does not have an immediate effect on the listing or trading of its common stock, but there is no assurance that the company will be able to regain compliance within the given timeframe.

Current Report Filed: 2026-03-31

Callan JMB Inc. reported its financial results for the year ended December 31, 2025, which are available in the attached press release.
The company is an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards.
No other material information was provided in the 8-K filing.

Annual Report Filed: 2026-03-31

The filing indicates that CALLAN JMB INC. (CJMB) has been actively engaged in acquisitions and reorganization, with the acquisition of ColdchainTechnology Services LLC in 2024 and the Exchange and Reorganization Agreement in late 2024.
CJMB appears to have a concentrated customer base, with four customers accounting for a significant portion of its sales revenue and accounts receivable in 2024 and 2025.
The company has invested in leasehold improvements, machinery, and other equipment, which could suggest expansion or enhancement of its operations.

Insider Trading Filed: 2026-03-26

The filing shows that David J. Croyle, a director and 10% owner of CALLAN JMB INC. (CJMB), acquired 10,195 shares of the company's common stock on March 20, 2026 at a price of $1.75 per share.
This transaction increases Croyle's beneficial ownership to 800,000 shares, which are held indirectly through a Rollover IRA.
Insider buying, especially by directors and large shareholders, can be a positive signal about the company's prospects and future stock performance.

Current Report Filed: 2026-03-12

Callan JMB Inc. has extended the maturity date of its Common Stock Purchase Agreement with Hexstone Capital, LLC to April 1, 2027, providing additional financial flexibility.
The company has revised the Regular Purchase Price to be 95% of the lowest daily trading price of the common stock, which could be more favorable for Callan JMB Inc. if the stock price declines.
The Investor's monthly resale limitation has been revised to the greater of $25,000 per Trading Day or 20% of the daily trading volume, potentially increasing liquidity for the stock.

Insider Trading Filed: 2026-03-10

David J. Croyle, Chief Medical Officer and 10% owner of CALLAN JMB INC., has purchased 14,805 shares of the company's common stock at $1.762 per share, increasing his indirect beneficial ownership to 789,805 shares.
The transaction indicates that an insider with significant ownership believes the company's stock is undervalued and sees potential for future growth.
Insider buying is often viewed as a positive signal for a company's prospects, as executives have strong incentives to generate shareholder value.

Current Report Filed: 2026-01-27

Callan JMB Inc. plans to make a series of investor presentations at the DealFlow Discovery Conference, starting on January 28, 2026, which could increase investor awareness and interest in the company.
The company anticipates making the investor presentations available on its website and through future 8-K filings, demonstrating a commitment to transparent communication with investors.
As an emerging growth company, Callan JMB Inc. has elected not to use the extended transition period for complying with new or revised financial accounting standards, which could signal a focus on meeting regulatory requirements.

Insider Trading Filed: 2026-01-06

The reporting person, Gerald Dial, acquired 2,000 shares of the issuer's common stock on December 30, 2025, indicating an increase in his direct ownership of the company's securities.
Dial was also granted a stock option to purchase 25,000 shares of the issuer's common stock, which vests on the first-year anniversary of the company's initial public offering.
The stock purchases and option grant suggest Dial's confidence in the company's future prospects and alignment with shareholder interests.

Current Report Filed: 2025-12-31

The company held its annual shareholder meeting on December 29, 2025, where all five director nominees were elected to serve a one-year term.
The shareholders ratified the appointment of Rosenberg Rich Baker Berman, P.A. as the company's independent registered public accounting firm for the fiscal year 2025.
The company reported that approximately 68.60% of the outstanding shares were present virtually or represented by proxy at the annual meeting.

Important Information